These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12506022)

  • 1. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.
    Pardanani A; Reeder T; Porrata LF; Li CY; Tazelaar HD; Baxter EJ; Witzig TE; Cross NC; Tefferi A
    Blood; 2003 May; 101(9):3391-7. PubMed ID: 12506022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
    Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
    Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
    Cortes J; Ault P; Koller C; Thomas D; Ferrajoli A; Wierda W; Rios MB; Letvak L; Kaled ES; Kantarjian H
    Blood; 2003 Jun; 101(12):4714-6. PubMed ID: 12595304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
    Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
    Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
    Pardanani A; Tefferi A
    Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
    Tan D; Hwang W; Ng HJ; Goh YT; Tan P
    Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
    Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M
    Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.
    Iurlo A; Gianelli U; Beghini A; Spinelli O; Orofino N; Lazzaroni F; Cambiaghi S; Intermesoli T; Rambaldi A; Cortelezzi A
    Oncotarget; 2014 Jul; 5(13):4665-70. PubMed ID: 25015329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
    Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
    N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C; Perla G; Minervini MM; Cascavilla N; Dell'Olio M; La Sala A; Mantuano S; Melillo L; Nobile M; Scalzulli PR; Bisceglia M; Carella AM
    Leuk Lymphoma; 2004 Jun; 45(6):1219-22. PubMed ID: 15360005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
    Stone RM; Gilliland DG; Klion AD
    Semin Oncol; 2004 Apr; 31(2 Suppl 6):12-7. PubMed ID: 15175999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome.
    Helbig G; Hus M; Hałasz M; Dudziński M; Więcławek A; Stachowicz M; Soja A; Kyrcz-Krzemień S
    Med Oncol; 2012 Jun; 29(2):1073-6. PubMed ID: 21258876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
    Wolf D; Gastl G; Rumpold H
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2104-6. PubMed ID: 15455302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
    Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
    Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
    Kindler T; Breitenbuecher F; Marx A; Hess G; Gschaidmeier H; Gamm H; Kirkpatrick CJ; Huber C; Fischer T
    Blood; 2003 Apr; 101(8):2960-2. PubMed ID: 12480706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A; Duggal L; Aggarwal S; Jain N
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement.
    Anghel G; De Rosa L; Ruscio C; Petti N; Riccardi M; Severino A; Majolino I
    Tumori; 2005; 91(1):67-70. PubMed ID: 15850007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
    Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
    Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.